STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2 (STAMP-2)
Mitral Valve Prolapse
About this trial
This is an interventional diagnostic trial for Mitral Valve Prolapse
Eligibility Criteria
Inclusion Criteria:
- Patient over 18 years old,
- Patient with mitral valve prolapse,
- Patient who has received full information about the organization of the research and has signed an informed consent,
- Patient affiliated to or beneficiary of a social security insurance,
- Patient who has completed a prior clinical examination adapted to the research and who does not show any contraindication to the planned examinations
Exclusion Criteria:
- Stage of the disease: Patients with MVP with severe mitral regurgitation with a surgical indication as defined by current recommendations will not be included in the study,
- Presence of severe rhythm disorders requiring the implantation of a defibrillator (cardiorespiratory arrest recovered, sudden death recovered, etc.),
- Performance of an injected MRI in the month preceding the MRI scheduled during visit n°1,
- Previously diagnosed cardiopathy that may be responsible for myocardial damage (ventricular remodeling, alteration of left ventricular systolic function, fibrosis, etc.) and that may disrupt the interpretation of results (infarction, amyloidosis, systemic scleroderma, significant aortic valvulopathy, etc.).
- Contraindication to MRI examination, particularly in the presence of an implantable pacemaker or defibrillator, implanted pump, cochlear implants, neurosurgical clips, intraorbital or encephalic metallic foreign bodies,
- Claustrophobia or morphotype that does not allow MRI to be performed,
- Motor or mental disability,
- Renal impairment that does not allow the injection of Gadolinium-based contrast media (DOTAREM® or equivalent in the study). If there is any doubt as to the patient's renal function, a plasma creatinine determination will be performed for MRI to ensure the absence of renal failure,
- Hypersensitivity to gadoteric acid, meglumine, or any gadolinium-containing drug.
- Women of childbearing age who do not have effective contraception,
- Persons referred to in Articles L. 1121-5 to L1121-8 of the Public Health Code.
Sites / Locations
- Nancy University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)
Group A (b) : patients without mitral regurgitation with ventricular extrasystole (>10/hour)
Group B : patients with Mitral valve prolapse with trivial mitral regurgitation
Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation
Group D : patients with asymptomatic Mitral valve prolapse with severe mitral regurgitation
These patients will undergo at the inclusion and 36 months after the inclusion : According to recommendations : echocardiography, 24-hour external loop recording and exercise ECG, And specifically for research purposes : injected cardiac MRI and a blood collection.
These patients will undergo at the inclusion and 36 months after the inclusion : According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI, And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection.
These patients will undergo at the inclusion and 36 months after the inclusion : According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI, And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection.
These patients will undergo at the inclusion and 36 months after the inclusion : According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI, And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection.
These patients will undergo at the inclusion and 36 months after the inclusion : According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI, And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection.